ABL Diagnostics submitted a bid on June 9, 2026, to acquire the business and assets of Texcell France, a company specializing in viral safety testing, immunology, and R&D services for biopharmaceutical products. The target company is currently subject to judicial reorganization proceedings before the Commercial Court of Évry. This strategic move by ABL Diagnostics aims to assess external growth opportunities complementary to its existing portfolio of molecular diagnostic solutions, healthcare software, and clinical sample management.

The proposed acquisition is based on Article L. 642-1 of the French Commercial Code. However, the transaction remains contingent upon the decision of the Commercial Court of Évry. At this stage, there is no certainty regarding the outcome of these insolvency proceedings. ABL Diagnostics stated it will keep the market informed of any significant developments in accordance with applicable regulatory obligations.

ABL Diagnostics specializes in innovative molecular biology tests and global solutions, including molecular polymerase chain reaction (PCR) detection under the UltraGene brand and genotyping by DNA sequencing under the DeepChek® brand. The company markets its products globally through its own sales team and a network of exclusive distributors. Its customer base includes academic clinical pathology laboratories, private reference laboratories, and researchers.

The company has an expanding portfolio of microbiology products, covering areas such as HIV drug resistance testing, SARS-CoV-2, Tuberculosis, Hepatitis B and C detection solutions, and microbiome analyses. Additionally, ABL Diagnostics offers integrated solutions like real-time syndromic PCR tests, the Nadis® Patient Medical Record used in over 200 hospitals in France, and MediaChek® Clinical Sample Collection Kits.

ABL Diagnostics has been marketing the products and services of its sister company CDL Pharma since the second half of 2025 through an intra-group strategy agreement. Headquartered in Woippy, ABL Diagnostics is a public limited company listed on compartment B of the regulated market of Euronext in Paris.

ABL Diagnostics has disclosed the total number of voting rights and shares composing its share capital as of May 22, 2026. The company reported 16,114,656 shares outstanding, providing transparency on its equity structure for shareholders and regulatory bodies.

The filing details the breakdown of voting rights, distinguishing between theoretical and exercisable figures. Theoretical voting rights are calculated on the basis of all shares to which voting rights are attached, including shares deprived of voting rights. In accordance with resolutions dated March 23, 2022, double voting rights are granted to all fully paid-up shares for which a registered holding in the name of the same shareholder for at least two years has been evidenced, effective from March 23, 2022.

The following table outlines the share capital and voting rights data:

| Date | Total number of shares composing the share capital | Total number of voting rights (1) (2) || | :--- | :--- | :--- | :--- || | | | Theoretical voting rights | Exercisable voting rights || | 22 mai 2026 | 16 114 656 | 30 846 644 | 30 814 120 ||

ABL Diagnostics specializes in innovative molecular biology tests and global solutions, including molecular polymerase chain reaction (PCR) detection under the UltraGene brand and genotyping by DNA sequencing under the DeepChek® brand. The company markets its products globally through its own sales team and a network of exclusive distributors.

The company's expanding portfolio includes HIV drug resistance testing, SARS-CoV-2, Tuberculosis, Hepatitis B and C detection solutions, and microbiome analyses. ABL Diagnostics has been marketing the products and services of its sister company CDL Pharma since the second half of 2025 through an intra-group strategy agreement.

ABL Diagnostics is headquartered in Woippy and is listed on compartment B of the regulated market of Euronext in Paris (Euronext: ABLD – ISIN: FR001400AHX6).